Shandong Suncadia Medicine Co., Ltd.
Registry sponsor category
Industry
- Other names
- Shandong Suncadia Medicine Co., Ltd.
- Company name
- Shandong Suncadia Medicine Co., Ltd.
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (86)
- A 16 Week Study of HRS-7535 in Adults With Type 2 Diabetes Mellitus
- A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants
- A Clinical Study Comparing the Bioavailability of HRS-2189 Tablets
- A Clinical Study of HRS-7156 in Healthy Participants
- A Clinical Study of Mass Balance of [14C]HRS-7535
- A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy
- A Clinical Study to Evaluate the Relative Bioavailability and Food Effect of HRS-8080 in Healthy Subjects
- A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
- A Clinical Trial of HRS-1301 on the Pharmacokinetics of Rosuvastatin Calcium Tablets in Healthy Subjects
- A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors
- A HR20031 BE Study on Healthy Subjects
- A HR20031 FE Study on Healthy Subjects
- A Mass Balance Study of [14C]HRS-1780 in Healthy Adult Male Subjects
- A Multiple Ascending Dose Trial of HRS-2129 in Healthy Subjects
- A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease
- A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
- A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour
- A Phase I Single- and Multiple- Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7535 in Healthy Subjects
- A Phase I Trial on the Relative Bioavailability and Food Effect of HRS-1893 Tablets in Healthy Subjects
- A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors